Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference in Belfast, Northern Ireland(1).

Tuberous sclerosis complex is a genetic disorder that may cause non-cancerous tumors to form in vital organs, including the brain (SEGAs) and kidney (angiomyolipomas)(3). These kidney tumors occur in up to 80% of patients, usually occurring between the ages of 15 and 30 and increasing in prevalence with age(2,3). Angiomyolipomas are the greatest cause of morbidity and mortality in adult TSC patients, as larger tumors may cause severe bleeding, require surgical intervention or result in kidney failure(2,3). Tumor symptoms may include nausea, vomiting, pain and bleeding(3,6,7).

Results of the 118-patient, randomized, placebo-controlled Phase III EXIST-2 (EXamining everolimus In a Study of TSC) trial showed 42% of patients (33 of 79) experienced a response in the everolimus arm versus 0% of patients (0 of 39) on placebo (p<0.0001) based on best overall response rate(1). These results add to the recent positive Phase III data from a separate trial in patients with TSC, which demonstrated reduction in the size of non-cancerous brain tumors (SEGAs) with everolimus(5).

"For the first time, a large placebo-controlled study has focused specifically on angiomyolipomas in TSC patients, an area with clear unmet need," said Dr. John Bissler, lead study author and Clark D. West Endowed Chair of Nephrology at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. "In addition to the tumor reduction seen with everolimus in this trial, s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 According to ... & Spine Surgery, Plastic and Reconstructive Surgery, Oncology, Ophthalmology, ... Outpatient Facilities) - Global Forecast to 2020", published by ... $806.6 Million by 2020 from $402.2 Million in 2014, ... Browse   7 6   ...
(Date:4/1/2015)... , Mar. 31, 2015 Research and ... the addition of the "Metabolic Testing Market ... System), by Application (Critical Care, Lifestyle Diseases), by ... (Gym, Sports, Hospital) - Global Forecast to 2019 ... The global metabolic testing market is expected to ...
(Date:4/1/2015)... Eli Lilly and Company (NYSE: LLY ) ... 2015 on Thursday, April 23, 2015.  Lilly will also conduct ... and media to further detail the company,s financial performance. ... Investors, media, and the general public can access a live ... be posted on Lilly,s website at www.lilly.com . A ...
Breaking Medicine Technology:Surgical Microscopes Market Worth $806.6 Million by 2020 2Surgical Microscopes Market Worth $806.6 Million by 2020 3Surgical Microscopes Market Worth $806.6 Million by 2020 4Global Metabolic Testing (CPET, Body Composition Analysis, ECG, Portable System) Market 2015-2019 - REE, Body Composition Analysis for Gyms, Sports & Hospital 2Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement 2
(Date:4/1/2015)... It all began at home in the kitchen of Shoosha ... mission to create a line of skincare for moms and ... Now, Shoosha Truly Organic is the only complete line of ... contain a minimum 95% certified organic ingredients, for babies and ... be 40% thinner than adults and of course much more ...
(Date:4/1/2015)... Springs, FL (PRWEB) April 01, 2015 ... nation’s leading innovative specialty pharmacies, has released a new ... latest treatment guidelines for treating chronic hepatitis C virus ... treatment guidelines based on information from the American Association ... credible, scientific sources. , Numerous new direct-acting oral medications ...
(Date:4/1/2015)... Northfield, IL, Bethesda, MD, Alexandria, VA (PRWEB) April ... for Clinical Pathology (ASCP), the College of American ... and the American Society of Clinical Oncology (ASCO) ... guideline on the use of molecular marker testing ... This evidence-based guideline will help establish standard molecular ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... SCI Solutions , the health industry’s leading ... CEO Joel French will be a featured speaker at ... in Chicago, April 12-16, 2015. French will co-present “ ... Strategies ” with Northeast Georgia Health System (NGHS) on ... 38,000 healthcare industry professionals are expected at the conference, ...
Breaking Medicine News(10 mins):Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4
... ... of a public health insurance option that competes with private insurance but do not support ... polls. , ... (PRWEB) December 24, 2009 -- PollingNumbers.com is a non-partisan website that tracks the polls on ...
... , , , LOS ANGELES, ... " presentation is being telecast over multiple broadcasts, cable and ... homes this year. Participating stars and other notables include Celine ... Kidman, Bob Costas, and Natalie Cole. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091223/DC30052 ...
... , , MINNEAPOLIS, Dec. 23 Quitting smoking is ... many Minnesotans. As the holiday approaches, QUITPLAN Services, the ... motivate them to make a fresh start with a ... to quit. The new ad acknowledges that every individual ...
... Care Provision Key to Reform , Statement by James P. ... WASHINGTON, Dec. 23 The National Council on Aging supports the ... which, when passed, will bring America one giant step closer to ... affordable for Americans of all ages. , NCOA has worked ...
... MARINA DEL REY, Calif., Dec. 23 Lakeside Medical ... by the Glendale Chamber of Commerce for significant community ... of Commerce, honored Lakeside in recognition of "outstanding contributions ... to patients and quality care." , Lakeside Medical Organization ...
... Inhibition of transcription factor E2F1 reduced epidermal growth factor ... not proliferation of metastatic melanoma cells, according to a ... Journal of the National Cancer Institute . To ... M.D., Ph.D., of the department of vectorology and experimental ...
Cached Medicine News:Health News:PollingNumbers.com: Pollsters Reveal Unanimous Discontent with Health Care Bill 2Health News:PollingNumbers.com: Pollsters Reveal Unanimous Discontent with Health Care Bill 3Health News:Top Stars Rally for Fighting Blindness, Sending Their Message out to 160 Million Homes on Multiple Cable Networks, December 25th, Preceded by President George Herbert Walker Bush Describing the Frank Capra Classic, 'It's A Wonderful Life' for the Bl 2Health News:Smokers: Resolve to Get the Monkey off Your Back in 2010 2Health News:Smokers: Resolve to Get the Monkey off Your Back in 2010 3Health News:NCOA Supports Senate Health Reform Bill 2Health News:NCOA Supports Senate Health Reform Bill 3Health News:Lakeside Medical Organization, Dr. Richard Merkin, CEO, Honored by Glendale Chamber of Commerce 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: